Regeneron Pharmaceuticals, Inc. (REGN) is listed on NasdaqGS in the Healthcare sector Β· Biotechnology industry. The current price is 844.52, down -0.88% from the previous close. Market cap is approximately $87.7B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Regeneron Pharmaceuticals, Inc. trades at a P/E of 20.37x, within the typical range for mature companies. Whether the multiple sits above or below the sector median is the cleaner relative-value read.
An ROE of 14.04% is standard territory. Without a clear differentiator, expect the figure to drift toward the industry mean over time.
Regeneron Pharmaceuticals, Inc.'s elevated D/E of 8.54 either reflects an aggressive growth-via-debt strategy or balance sheet stress. Operating cash flow trend is the cleanest tell.
Regeneron Pharmaceuticals, Inc.'s 16.70% revenue growth signals strong momentum. The quality (price vs volume, new vs existing customers) determines whether it is sustainable.
Dividend yield of 0.46% is on the low side. Capital is more likely going to reinvestment and buybacks than payouts.
Pharma and biotech are typically valued through risk-adjusted NPV/DCF on the pipeline.
Regeneron Pharmaceuticals, Inc. is near its 52-week high (859.34), in the top 5% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The stock moved within a 2.59% high-to-low band on the day, closing -0.88%. That falls within a typical intraday range.
Regeneron Pharmaceuticals, Inc. (REGN) is listed on NasdaqGS, with recent volume of 210,534 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.